CORONA, Calif. Drug developer Watson Pharmaceuticals said Friday it named Mark Durand as senior vice president and chief financial officer.
Durand, 48, previously worked as chief financial officer at Teva Pharmaceuticals. He assumes the position left by Charles P. Slacik, who resigned in October 2006 to become chief financial officer of Beckman Coulter.
R. Todd Joyce, vice president, corporate controller and principal accounting officer, has served as interim principal financial officer.
Watson is a leading specialty pharmaceutical company that is best known for developing and marketing generic versions of well-known drugs.